Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients (NCT04824092)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL)
🩺 Plain-English Summary (8th-Grade Level)
This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial designed to compare the efficacy and safety of the humanized monoclonal anti CD19 antibody tafasitamab plus lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed DLBCL
Who can join: Review the eligibility criteria below.
Location: MorphoSys Research Site — Daphne, Alabama
Age range: 18 Years to 80 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (307 Sites)
Showing the first 25 of 307 sites.
- MorphoSys Research Site — Daphne, Alabama
- MorphoSys Research Site — Anaheim, California
- MorphoSys Research Site — Clovis, California
- MorphoSys Research Site — Fullerton, California
- MorphoSys Research Site — Harbor City, California
- MorphoSys Research Site — Los Angeles, California
- MorphoSys Research Site — San Diego, California
- MorphoSys Research Site — Whittier, California
- MorphoSys Research Site — Aurora, Colorado
- MorphoSys Research Site — Jacksonville, Florida
- MorphoSys Research Site — Honolulu, Hawaii
- MorphoSys Research Site — Wichita, Kansas
- MorphoSys Research Site — Lexington, Kentucky
- MorphoSys Research Site — Louisville, Kentucky
- MorphoSys Research Site — Baltimore, Maryland
- MorphoSys Research Site — Bethesda, Maryland
- MorphoSys Research Site — Columbia, Maryland
- MorphoSys Research Site — Detroit, Michigan
- MorphoSys Research Site — Minneapolis, Minnesota
- MorphoSys Research Site — Rochester, Minnesota
- MorphoSys Research Site — Kansas City, Missouri
- MorphoSys Research Site — Lebanon, New Hampshire
- MorphoSys Research Site — Florham Park, New Jersey
- MorphoSys Research Site — Buffalo, New York
- MorphoSys Research Site — Rochester, New York
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Diffuse Large B-cell Lymphoma
- A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) — Tucson, Arizona
- Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas — Birmingham, Alabama
- A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) — Tucson, Arizona
- A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) — Rochester, New York
- Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma — Cleveland, Ohio
Explore by condition: All Diffuse Large B-cell Lymphoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.